MX394766B - Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. - Google Patents
Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.Info
- Publication number
- MX394766B MX394766B MX2018013873A MX2018013873A MX394766B MX 394766 B MX394766 B MX 394766B MX 2018013873 A MX2018013873 A MX 2018013873A MX 2018013873 A MX2018013873 A MX 2018013873A MX 394766 B MX394766 B MX 394766B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- irinotecan
- lung cancer
- small cell
- cell lung
- Prior art date
Links
- 206010041067 Small cell lung cancer Diseases 0.000 title abstract 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 3
- 229960004768 irinotecan Drugs 0.000 title abstract 3
- 208000000587 small cell lung carcinoma Diseases 0.000 title abstract 3
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US201762474661P | 2017-03-22 | 2017-03-22 | |
| PCT/IB2017/000681 WO2017199093A1 (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013873A MX2018013873A (es) | 2019-02-14 |
| MX394766B true MX394766B (es) | 2025-03-24 |
Family
ID=59258274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013873A MX394766B (es) | 2016-05-18 | 2017-05-17 | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230000858A1 (enExample) |
| EP (1) | EP3458059A1 (enExample) |
| JP (3) | JP2019516693A (enExample) |
| KR (1) | KR20190009319A (enExample) |
| CN (1) | CN109640995A (enExample) |
| AU (1) | AU2017267449A1 (enExample) |
| BR (1) | BR112018072988A2 (enExample) |
| CA (1) | CA3023743A1 (enExample) |
| IL (1) | IL262656A (enExample) |
| MA (1) | MA45046A (enExample) |
| MX (1) | MX394766B (enExample) |
| PH (1) | PH12018502422A1 (enExample) |
| SG (2) | SG11201809788VA (enExample) |
| TW (1) | TWI791437B (enExample) |
| UA (1) | UA125646C2 (enExample) |
| WO (1) | WO2017199093A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| EP3791876A1 (en) | 2015-08-21 | 2021-03-17 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| ES3036518T3 (en) | 2015-10-16 | 2025-09-19 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
| RU2761953C2 (ru) | 2016-11-02 | 2021-12-14 | Ипсен Биофарм Лтд. | Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101462825B1 (ko) * | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| WO2009097011A1 (en) * | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/zh active Pending
- 2017-05-17 MX MX2018013873A patent/MX394766B/es unknown
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/en not_active Withdrawn
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/pt not_active Application Discontinuation
- 2017-05-17 CA CA3023743A patent/CA3023743A1/en active Pending
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/en not_active Ceased
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 MA MA045046A patent/MA45046A/fr unknown
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/ko not_active Ceased
- 2017-05-17 UA UAA201812255A patent/UA125646C2/uk unknown
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/ja not_active Withdrawn
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-18 TW TW106116523A patent/TWI791437B/zh active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/ja not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/ja active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA45046A (fr) | 2019-03-27 |
| JP2019516693A (ja) | 2019-06-20 |
| IL262656A (en) | 2018-12-31 |
| PH12018502422A1 (en) | 2019-03-11 |
| SG11201809788VA (en) | 2018-12-28 |
| KR20190009319A (ko) | 2019-01-28 |
| TWI791437B (zh) | 2023-02-11 |
| TW201740946A (zh) | 2017-12-01 |
| AU2017267449A1 (en) | 2018-11-15 |
| UA125646C2 (uk) | 2022-05-11 |
| SG10201912407YA (en) | 2020-02-27 |
| EP3458059A1 (en) | 2019-03-27 |
| CN109640995A (zh) | 2019-04-16 |
| MX2018013873A (es) | 2019-02-14 |
| CA3023743A1 (en) | 2017-11-23 |
| BR112018072988A2 (pt) | 2019-04-09 |
| WO2017199093A1 (en) | 2017-11-23 |
| US20230000858A1 (en) | 2023-01-05 |
| JP2020117548A (ja) | 2020-08-06 |
| JP2022010295A (ja) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013873A (es) | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. | |
| ECSP17048849A (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX392408B (es) | Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina). | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX385425B (es) | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. | |
| MX2018001723A (es) | Conjugados farmaco-multiligando y usos de los mismos. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
| MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX383682B (es) | Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional. | |
| GT201400071A (es) | Combinación terapéutica para el tratamiento de cáncer | |
| EA201892592A1 (ru) | Лечение мелкоклеточного рака легких с помощью липосомального иринотекана | |
| DOP2017000174A (es) | Terapias de combinación para el tratamiento de cánceres | |
| HK1242199A1 (en) | Treatment of cancer using tlr9 agonist with checkpoint inhibitors | |
| AR106220A1 (es) | Conjugados homogéneos específicos de sitio con inhibidores de ksp | |
| AR078798A1 (es) | Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona |